Although the fluoroquinolones are the drugs of choice for invasive Salmonella infections, recently reduced ciprofloxacin susceptibility and therapeutic failures have been reported from many countries. The purpose of this study was to determine reduced ciprofloxacin susceptibity among Salmonella enterica strains isolated in the routine laboratory. A total of 133 Salmonella enterica isolates collected between 1997-2005 were studied retrospectively. Nalidixic acid and ciprofloxacin susceptibilities were investigated by disk diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines, also ciprofloxacin MIC values were determined by E-test. Reduced ciprofloxacin susceptibility was described as MIC values ≤ 1 µg/ml - ≥ 0.125 µg/ml. Ciprofloxacin MIC values of all 133 isolates were between 0.004-0.25 µg/ml. Twenty two isolates were classified as nalidixic acid resistant while the rest 111 were evaluated as sensitive. Ciprofloxacin MIC values of these 111 strains were ≤ 0.064 µg/ml and 22 isolates had MIC's between 0.125-0.25 µg/ml. Isolates for which the ciprofloxacin MICs were ≤ 0.064 µg/ml had inhibition zone diameters ≥ 33 mm for nalidixic acid whereas isolates showing decreased ciprofloxacin susceptibility had zone diameters of 25-32 mm. Among the S. enterica strains isolated in the laboratory 16.5% reduced ciprofloxacin susceptibility and nalidixic acid resistance were detected. To determine the reduced ciprofloxacin susceptibility, screening nalidixic acid resistance by disk diffusion was observed to be helpful.